Dr. Farley Banned from Drugs: DEA Revokes Indiana Doc's License
Published Date: 9/29/2026
Notice
Summary
Dr. Johann Farley from Indiana lost his DEA registration because he was kicked out of Medicare, Medicaid, and other federal health programs. This means he can no longer legally handle controlled substances starting September 30, 2025. The DEA made this decision official in 2026 to keep healthcare and drug laws strong and clear for everyone.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
DEA registration revoked for Dr. Farley
The DEA revoked Certificate of Registration No. BF8869628 issued to Johann Farley, M.D. The Order revoking his registration is effective October 29, 2026.
Pending renewals and new registrations denied
The Order denies any pending applications of Johann Farley, M.D., to renew or modify Registration No. BF8869628 and denies any other pending application for additional registration in Indiana. That denial is part of the Order effective October 29, 2026.
Mandatory exclusion from federal health programs
Based on a conviction, the U.S. Department of Health and Human Services, Office of Inspector General mandatorily excluded Johann Farley, M.D., from Medicare, Medicaid, and all Federal health care programs effective May 20, 2025 for a minimum period of 12 years.
Guilty plea to health care fraud recorded
The record states that on June 11, 2024, Johann Farley, M.D., pleaded guilty to one count of health care fraud in the U.S. District Court for the Northern District of Indiana.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2026-19820, Product Change-Priority Mail Express, Priority Mail, and USPS Ground Advantage Negotiated Service Agreements; Priority Mail, and USPS Ground Advantage Negotiated Service Agreements
The Postal Service is updating its shipping deals for Priority Mail Express, Priority Mail, and USPS Ground Advantage by adding new negotiated service agreements. These changes affect businesses and customers who use these shipping options, potentially offering new pricing or service perks. The updates were officially filed in late September 2026 and could impact shipping costs and options soon.
Next: 2026-19822, Agency Information Collection Activities; Submission for OMB Review; Comment Request; Access to Employee Exposure and Medical Records
The Department of Labor wants your thoughts on how they collect and share workers’ exposure and medical records to keep employees safe from harmful chemicals and conditions. Employers must keep these records and let workers see them. Comments are open until October 29, 2026, and this review helps make sure the process is clear, useful, and not too much work or cost for anyone.